RuSmolikova wrote:The number of PML patients (MS sufferers treated with Tysabri) has raised from 145 at the beginning of July to 150 at the beginning of August. One new case is in USA and the next four live in Europe.
HarryZ wrote:...Not as high an increase than in previous months but I'm hearing that the number of patients on Tysabri has not been growing and some patients on it for 3 years have been taken off as a precaution to PML.
HarryZ wrote:Oh Biogen is still making a killing off Tysabri regardless that the level of increase in patients is slowing down. Part of that 28% revenue increase year over year is due to a price hike at the wholesale level.
Bingo! It´s easy to calculate.
As of the end of June 2010, Biogen Idec had approximately 52,700 patients on therapy, including about 600 in clinical trials. And the company ended the 2nd quarter of 2011 with 61,500 patients, an increase of 2,400 over the last quarter.
Almost ten thousand patients a year is not as good result considering that they sell the most efficient drug on the market. As far as I remember they didn´t meet their ambitious plans to have 100,000 MS patients on Tysabri by the end of 2010...
Users browsing this forum: No registered users